Reference is made to the stock exchange announcement from SoftOx Solutions AS
(the "Company") on 29 December 2021 regarding the Company's extraordinary
general meeting resolving to issue 259,403 new shares in the Company against a
set-off of NOK 9,999,985.65 of Almhaug Bolig AS' claim against the Company under
a loan agreement dated 13 October 2021.  

The share capital increase pertaining to the debt conversion of NOK 5,188.06
divided on 259,403 shares has today been registered in the Norwegian Register of
Business Enterprises (Nw: Foretaksregisteret).   

Following the share capital increase, the new share capital in the Company is
NOK 206,857.42 divided into 10,342,871 shares, each with a nominal value of NOK
0.02.  

The new shares will be listed and tradable on Euronext Growth Oslo from issuance
in the Central Securities Depository (VPS). 

For further information, please contact: 
CEO Geir Almås of SoftOx Solutions AS, or 
CFO Kristine Rød of SoftOx Solutions AS 
Mail: ir@soft-ox.com 
Mobile: (+47) 948 59 599 

About SoftOx Solutions AS 
SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a Norwegian
BioTech company based in Oslo with the aim of helping to combat major threats to
human health, namely the emergence of antimicrobial resistance (AMR), biofilm
infections in chronic wounds and the spread of viruses. For more information on
SoftOx, visit www.soft-ox.com